Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3046 - Monitoring patient-specific mutation in ctDNA and CTC for tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric cancer (NCT03425058)

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Gastric Cancer

Presenters

Tao Fu

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

T. Fu

Author affiliations

  • Gastrrointestinal Surgery, Peking University Cancer Hospital-Beijing Cancer Hospital, 100142 - Beijing/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3046

Background

We conduct a trial using neoadjuvant chemotherapy (nCRT) and verify the value of ctDNA and CTC as biomarkers for tumor response in the nCRT treatment of locally advance gastric adenocarcinoma.

Methods

Twenty milliliters of plasma were collected at 3 points: before nCRT; after 2 cycles of nCRT; and after surgery. Firefly ctDNA NGS assays were used to track ctDNA mutations previously characterized in paired tumor tissue by massively parallel sequencing. Using patient-specific mutation derived from exome sequencing of tumor tissues samples, bespoke amplicon-based sequencing panel were synthesized and used for ctDNA profiling. CTCs in 7ml peripheral blood were separated by a negative enrichment method and identified by FISH using two frequently proliferation chromosome probes, CEP8 and CEP17. Meanwhile, the HER2 expression in CTCs was determined by FISH and immunofluorescence. CEP8+ and/or CEP17+, DAPI+, CD45- cell were justified as CTCs, HER2 FISH+ or HER2 IF+, DAPI+, CD45- cells were justified as HER2 positive CTCs.

Results

In comparison to basal line value of pre-chemotherapy blood, the ctDNA loading were decreased in post-chemotherapy specimens of 8 patients with TRG1 by histopathological grading or partial and complete response by CT scan. However, the amount of ctDNA in 25 patients diagnosed as TRG 2 or 3 showed minor changes during the neoadjuvant therapy. 22 have integral FISH data (CTCs range from 0-29, average: 4.9, 2.7 and 4.0, positive rate: 82%,73% and 73%), and 12 have integral HER2 data (CTCS range from 0-9, average: 2.9, 2.2 and 2.9, positive rate: 25%, 50% and 33%). The dynamic variations were coincidence to the clinical evaluation. For HER2, we found three positive model in CTCs, single FISH or IF positive or double positive. Double positive HER2-CTCs are found in some patients. By negative enrichment and FISH, CTCs can be detected at a low cutoff of 2 cells in 73%∼82% patients.

Conclusions

The ctDNA and CTC alteration during neoadjuvant therapy are consistent with histopathological grading and response assessmentand and can be surrogate markers to prediction efficacy of nCRT for GC.

Clinical trial identification

NCT03425058 11/02/2018.

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Beijing Municipal Administration of Hospital Clinical Medicine Development of Special Funding Support (ZYLX201701).

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.